Literature DB >> 35048238

ASO Author Reflections: Improvement of Esophageal Cancer Staging by Implementing Mandard Tumor Regression Score.

D J Crull1, M C H Hogenes2, R Hoekstra3, E M Hendriksen4, M J van Det5, E A Kouwenhoven5.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35048238     DOI： 10.1245/s10434-022-11338-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  4 in total

1.  8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice.

Authors:  Thomas W Rice; Deepa T Patil; Eugene H Blackstone
Journal:  Ann Cardiothorac Surg       Date:  2017-03

2.  Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.

Authors:  Milan Vošmik; Jan Laco; Igor Sirák; Josef Dvořák; Petr Lochman; Miroslav Hodek; Petra Malá; Stanislav Rejchrt; Rudolf Repák; Michal Leško; Alexander Ferko; Aleš Ryška; Bohuslav Melichar; Jiří Petera
Journal:  Pathol Oncol Res       Date:  2017-05-27       Impact factor: 3.201

3.  Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations.

Authors:  A M Mandard; F Dalibard; J C Mandard; J Marnay; M Henry-Amar; J F Petiot; A Roussel; J H Jacob; P Segol; G Samama
Journal:  Cancer       Date:  1994-06-01       Impact factor: 6.860

4.  Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.

Authors:  Ronan J Kelly; Jaffer A Ajani; Jaroslaw Kuzdzal; Thomas Zander; Eric Van Cutsem; Guillaume Piessen; Guillermo Mendez; Josephine Feliciano; Satoru Motoyama; Astrid Lièvre; Hope Uronis; Elena Elimova; Cecile Grootscholten; Karen Geboes; Syed Zafar; Stephanie Snow; Andrew H Ko; Kynan Feeney; Michael Schenker; Piotr Kocon; Jenny Zhang; Lili Zhu; Ming Lei; Prianka Singh; Kaoru Kondo; James M Cleary; Markus Moehler
Journal:  N Engl J Med       Date:  2021-04-01       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.